<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897919</url>
  </required_header>
  <id_info>
    <org_study_id>Eurartesim2015</org_study_id>
    <nct_id>NCT04897919</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau</brief_title>
  <official_title>Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bandim Health Project</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bandim Health Project</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: to measure the effectiveness and safety of (artemether-lumefantrine) AL and&#xD;
      (dihydroartemisinin-piperaquine) DP in patients (&gt; 6 months) suffering from uncomplicated P.&#xD;
      falciparum malaria.&#xD;
&#xD;
      Patients coming to Bandim Health Center will, if accepting, be randomised to study-arm.&#xD;
      Medication will be provided and first dose given. Patients will be followed-up on day 7, 14,&#xD;
      28, and 42 with clinical evaluation, malaria film and filter-paper blood-sample for&#xD;
      polumerase chain reaction (PCR) on re-appearing parasites. On day 21 and 35 a&#xD;
      telephone-interview will be performed.&#xD;
&#xD;
      Primary out-come: adequate clinical and parasitological response rate on day 42. Secondary&#xD;
      out-comes: safety, re-infection vs recrudescence, and haemoglobin on day 42.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To objective of the study:&#xD;
&#xD;
        1. To measure the efficacy and safety of AL and DP in children for treating uncomplicated&#xD;
           P. falciparum malaria.&#xD;
&#xD;
        2. To determine the capacity of each drug combination to protect against re-infection.&#xD;
&#xD;
        3. To differentiate recrudescence from re-infections using PCR based methods&#xD;
&#xD;
        4. To determine haemoglobin values on days 0 and 42&#xD;
&#xD;
        5. To determine genetic polymorphisms in P. falciparum causing reparasitaemia. Study design&#xD;
           This will be an open label, randomized, non inferiority trial conducted at the Bandim&#xD;
           Health Centre, Guinea-Bissau. Patients with uncomplicated malaria who meet study&#xD;
           inclusion criteria will be enrolled, randomised to treatment with either AL or DP.&#xD;
           Medication will be provided and first dose given at the health centre.&#xD;
&#xD;
      Efficacy and safety evaluation Treatment outcomes will be early treatment failure, late&#xD;
      clinical failure, late parasitological failure or adequate clinical and parasitological&#xD;
      response as defined by the WHO. All will be asked routinely about previous symptoms and about&#xD;
      symptoms that have emerged since the previous follow up visit. All adverse events will be&#xD;
      recorded in the case record forms.&#xD;
&#xD;
      100µL of blood will be collected on Whatman 3MM filter-paper using a capillary tube on day 0,&#xD;
      7, 14, 28,and 42 and whenever re-parasitaemia is detected. Filter-papers will be dried and&#xD;
      then placed inside separate sealed plastic bags.&#xD;
&#xD;
      In order to differentiate recrudescence from a re-infection genotyping using sequential&#xD;
      analysis of pf-glurp, pfmsp1 and pfmsp2 will be done. Drug concentrations will be assessed on&#xD;
      the week prior to re-parasitaemia. Haemoglobin concentration will be determined on day 0, 3&#xD;
      and 42 using a haemocueTM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate clinical and parasitological response rate at day 42</measure>
    <time_frame>Day 42</time_frame>
    <description>Cumulative percentages of children having successful treatment on day 42.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>re-infection vs recrudescence</measure>
    <time_frame>Day 42</time_frame>
    <description>Cumulative re-infection and recrudescence rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin level</measure>
    <time_frame>Day 42</time_frame>
    <description>Haemoglobin measured on day 42</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">474</enrollment>
  <condition>Malaria</condition>
  <condition>Effectiveness</condition>
  <arm_group>
    <arm_group_label>dihydroartemisinin-piperaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose will be given supervised. The rest will be provided and the parents should take it at home.&#xD;
Dihydroartemisinin-piperaquine dosing as recommended by manufacturer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>artemether-lumefantrine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>First dose will be given supervised. The rest will be provided and the patients should take it at home.&#xD;
Artemether-lumefantrine dosing as recommended by manufacturer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dihydroartemisinin-piperaquine</intervention_name>
    <description>D-P is given as recommended by manufacturer and compared to the A-L group.</description>
    <arm_group_label>dihydroartemisinin-piperaquine</arm_group_label>
    <other_name>Eurartesim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mono-infection with P. falciparum detected by microscopy.&#xD;
&#xD;
          -  Parasitemia of 1.000-200.000/µl asexual forms.&#xD;
&#xD;
          -  Axillary temperature ≥37.5 ˚C or a history of fever within 24 hours.&#xD;
&#xD;
          -  Ability to swallow oral medication.&#xD;
&#xD;
          -  Ability and willingness to comply with the study protocol for the duration of the&#xD;
             study and to comply with the study visit schedule.&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs or symptoms of severe malaria&#xD;
&#xD;
          -  Presence of general danger signs in children under 5&#xD;
&#xD;
          -  Presence of severe malnutrition.&#xD;
&#xD;
          -  Any evidence of chronic disease or acute infection other than malaria.&#xD;
&#xD;
          -  Regular medication which may interfere with antimalarial pharmacokinetics.&#xD;
&#xD;
          -  History of hypersensitivity reactions or contraindications to AL, DP or quinine.&#xD;
&#xD;
          -  Domicile outside the study area.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bandim Health Centre</name>
      <address>
        <city>Bissau</city>
        <state>Bissau Codex</state>
        <country>Guinea-Bissau</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guinea-Bissau</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Artenimol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

